BioNTech shares rose 3.6% after earnings, with investors responding to encouraging lung-cancer data and progress toward pivotal trials. The pipeline remains the main catalyst; the transcript provides no new financial outlook or near-term commercial catalyst.
BioNTech posted significant advancements in its oncology pipeline during Q3 2025, reinforcing its position as a leader in immunotherapy development with promising updates on both Pumitamig and mRNA cancer therapies.